Metformin induces significant reduction of body weight, total cholesterol and LDL levels in the elderly - A meta-analysis.

ABSTRACT:

Background

Metformin is the first-choice drug for patients with Type 2 diabetes, and this therapy is characterized by being weight neutral. However, in the elderly an additional unintentional weight loss could be considered as an adverse effect of the treatment.

Objectives

We aimed to perform a meta-analysis of placebo-controlled studies investigating the body weight changes upon metformin treatment in participants older than 60 years.

Materials and methods

PubMed, EMBASE and the Cochrane Library were searched. We included at least 12 week-long studies with placebo control where the mean age of the metformin-treated patients was 60 years or older and the body weight changes of the patients were reported. We registered our protocol on PROSPERO (CRD42017055287).

Resu

SUBMITTER: Solymar M 

PROVIDER: S-EPMC6258123 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature